Geary Richard S, EVP and Chief Development Officer, has demonstrated a clear pattern of selling activity in Ionis Pharmaceuticals (IONS) over the past year, as evidenced by SEC Form 4 filings. Since January 2025, Geary has executed 38 trades, all involving IONS, with a total sell value of $14,907,242.65 and a total buy value of $9,368,875.67. Notably, all recent transactions have been sales, with 13 sell trades recorded since October 2025. Significant transactions include a $3,777,668.13 sale on September 30, 2025, and a $2,603,554.11 sale on October 31, 2025. Smaller but consistent sales were also made in November 2025, such as $138,020.43 and $112,152.53 on November 6, and $60,083.01 on November 5. This activity suggests a sustained divestment strategy, with Geary reducing his holdings in IONS over time.
The absence of recent purchases further underscores this trend. While Geary’s total buy value remains substantial, it is primarily driven by earlier transactions, such as a $9,368,875.67 purchase recorded prior to 2025. The recent focus on selling aligns with a broader pattern of reducing exposure to IONS, though the reasons behind this strategy remain undisclosed. Geary’s consistent and high-value sales indicate a deliberate shift in his investment position, reflecting a significant reduction in his stake in the company. This activity provides transparency into his financial decisions but does not imply any specific insight into Ionis Pharmaceuticals’ future performance.
AI-assisted summary